|1.||Kim, Kyeong Ho: 1 article (07/2007)|
|2.||Trung, Tran Quoc: 1 article (07/2007)|
|3.||Oh, Joung Weon: 1 article (07/2007)|
|4.||Sin, Kwan Seog: 1 article (07/2007)|
|5.||Kang, Jong Seong: 1 article (07/2007)|
|6.||Ogimoto, Akiyoshi: 1 article (12/2002)|
|7.||Shigematsu, Yuji: 1 article (12/2002)|
|8.||Ohtsuka, Tomoaki: 1 article (12/2002)|
|9.||Matsunaka, Tsuyoshi: 1 article (12/2002)|
|10.||Suzuki, Jun: 1 article (12/2002)|
|1.||Hypertension (High Blood Pressure)
03/01/1986 - "Bevantolol administered once daily or twice daily was equally effective in the management of hypertension and was well tolerated in the doses studied."
11/26/1986 - "The antihypertensive efficacy of bevantolol, a selective beta 1-adrenoreceptor antagonist, was evaluated in 17 patients with essential hypertension, using continuous ambulatory intraarterial blood pressure (BP) monitoring. "
03/01/1986 - "Two multicenter, double-blind, placebo-controlled studies were conducted to determine in patients with hypertension the oral dose of bevantolol that would effectively reduce home diastolic blood pressure to less than 95 mm Hg. The two studies differed only in once-daily or twice-daily dose administration. "
04/01/1995 - "Clinical evaluation of bevantolol hydrochloride in patients with severe hypertension. "
07/01/1993 - "These results show that bevantolol can inhibit both the hypertension and downregulation of the central beta 1-adrenoceptors induced by stress."
11/26/1986 - "Usefulness of bevantolol for chronic, stable angina pectoris."
09/01/1986 - "The efficacy and safety of bevantolol (new cardioselective beta-blocking agent without intrinsic sympathetic activity) were evaluated in chronic stable angina pectoris. "
03/01/1986 - "Bevantolol appeared to be an effective, well-tolerated drug in the management of angina pectoris."
03/01/1986 - "The antianginal efficacy and safety of bevantolol was compared with placebo in 107 patients with angina pectoris of effort. "
01/01/1988 - "However, although the properties of bevantolol may offer theoretical advantages in some patients, only a few comparative studies have been reported, and thus it is presently unclear what advantages bevantolol may offer over existing treatments for hypertension or angina pectoris."
|3.||Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
12/01/2002 - "This study was designed to compare the efficacy of bevantolol, a beta(1)-selective blocker with alpha-blockade and vasodilating activity, with that of metoprolol, a beta(1)-selective receptor blocker, for the treatment of idiopathic dilated cardiomyopathy (DCM). "
12/01/2002 - "Comparison of treatment effects of bevantolol and metoprolol on cardiac function and natriuretic peptides in patients with dilated cardiomyopathy."
11/26/1986 - "Bevantolol (0.5 or 1.5 mg/kg IV) gave full protection against ventricular fibrillation during the first period (10 minutes) of proximal left anterior descending (LAD) coronary artery occlusion in the highest dose. "
11/26/1986 - "After permanent ligation of the LAD coronary artery at midpoint, bevantolol prevented ventricular fibrillation during the first phase of early ventricular arrhythmias but was unable to prevent it during the second phase of early arrhythmias. "
|5.||Coronary Artery Disease (Coronary Atherosclerosis)
|4.||Antihypertensive Agents (Antihypertensives)
|5.||4- chloro- 3',6'- dimethyl- 2,2'- iminodibenzoate (TO 115)
|8.||Adrenergic Antagonists (Antiadrenergic Agents)
|10.||Adrenergic Receptors (Adrenergic Receptor)